more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$884.22 USD

-6.85 (-0.77%)

Updated Oct 3, 2024 03:55 PM ET

After-Market: $885.35 +1.13 (0.13%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat

by Zacks Equity Research Published on July 30,2020

United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

pharmaceuticals

Lilly (LLY) Q2 Earnings Top Estimates, Sales Lag, Stock Down

by Zacks Equity Research Published on July 30,2020

Eli Lilly (LLY) reports mixed Q2 results. Total revenues in the quarter hurt by the coronavirus pandemic

pharmaceuticals

Eli Lilly (LLY) Q2 Earnings Top Estimates

by Zacks Equity Research Published on July 30,2020

Lilly (LLY) delivered earnings and revenue surprises of 19.62% and -2.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

LLYNegative Net Change

5 Spectacular Earnings Charts

by Tracey Ryniec Published on July 29,2020

These 5 stocks are breaking out to new 5-year highs heading into their earnings reports. Can they keep that momentum?

Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More

by Kinjel Shah Published on July 29,2020

Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.

How Hard Will Coronavirus Hit Lilly's (LLY) Q2 Earnings?

by Zacks Equity Research Published on July 27,2020

Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports second-quarter earnings.

pharmaceuticals

Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data

by Kinjel Shah Published on July 24,2020

Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.

pharmaceuticals

3 Strong Dividend Stocks to Buy Now for Income & Coronavirus Growth

by Benjamin Rains Published on July 23,2020

Let's dive into three stocks that are projected to grow during the pandemic that also provide solid income through dividends...

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research Published on July 23,2020

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LLYNegative Net Change

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research Published on July 20,2020

In the latest trading session, Eli Lilly (LLY) closed at $167.04, marking a +0.65% move from the previous day.

LLYNegative Net Change

Lilly's Plaque Psoriasis Candidate Meets Phase III Study Goals

by Zacks Equity Research Published on July 20,2020

Lilly's (LLY) autoimmune disorder candidate, mirikizumab, superior to Cosentyx in a phase III study for patients with moderate-to-severe plaque psoriasis.

pharmaceuticals

AstraZeneca's Farxiga Gets Fast Track Tag for New Indication

by Zacks Equity Research Published on July 17,2020

AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.

pharmaceuticals

Zacks.com featured highlights include: BJ's Wholesale Club, Eli Lilly, Sprouts Farmers Market, Kroger and Everbridge

by Zacks Equity Research Published on July 16,2020

Zacks.com featured highlights include: BJ's Wholesale Club, Eli Lilly, Sprouts Farmers Market, Kroger and Everbridge

J&J (JNJ) Beats on Q2 Earnings & Sales, Ups 2020 Guidance

by Zacks Equity Research Published on July 16,2020

J&J (JNJ) beats second-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.

pharmaceuticals

Glaxo's Multiple Myeloma Candidate Gets FDA Committee Nod

by Zacks Equity Research Published on July 15,2020

Glaxo's (GSK) belantamab mafodotin gets FDA's Oncologic Drugs Advisory Committee votes as its benefits outweigh risks for relapsed/refractory multiple myeloma patients.